Triglyceride-rich lipoproteins as a causal factor for cardiovascular disease

References

• Cholesterol Treatment Trialists’ (CTT) CollaborationFulcherJO’ConnellREfficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trialsLancet201538599761397140525579834
   PubMed Web of Science ®Google Scholar
• ChapmanMJGinsbergHNAmarencoPTriglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for managementEur Heart J201132111345136121531743
   PubMed Web of Science ®Google Scholar
• JellingerPSSmithDAMehtaAEAmerican Association of Clinical Endocrinologists’ guidelines for management of dyslipidemia and prevention of atherosclerosisEndocr Pract201218suppl 117822522068
   PubMedGoogle Scholar
• CatapanoALReinerZDe BackerGESC/EAS guidelines for the management of dyslipidaemias. The task force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS)Atherosclerosis2011217134621882396
   PubMed Web of Science ®Google Scholar
• SampsonUKFazioSLintonMFResidual cardiovascular risk despite optimal LDL cholesterol reduction with statins: the evidence, etiology, and therapeutic challengesCurr Atheroscler Rep201214111022102062
   PubMed Web of Science ®Google Scholar
• BoekholdtSMArsenaultBJMoraSAssociation of LDL cholesterol, non-HDL cholesterol, and apolipoprotein B levels with risk of cardiovascular events among patients treated with statins: a meta-analysisJAMA2012307121302130922453571
   PubMed Web of Science ®Google Scholar
• CarrollMKitBLacherDTrends in elevated triglyceride in adults: United States, 2001–2012NCHS Data Brief201519819825973997
   PubMedGoogle Scholar
• HegeleRAGinsbergHNChapmanMJThe polygenic nature of hypertriglyceridaemia: implications for definition, diagnosis, and managementLancet Diabetes Endocrinol20142865566624731657
   PubMed Web of Science ®Google Scholar
• BrunzellJDSchrottHGThe interaction of familial and secondary causes of hypertriglyceridemia: role in pancreatitisJ Clin Lipidol20126540941223009776
   PubMed Web of Science ®Google Scholar
• MillerMCannonCPMurphySAPROVE IT-TIMI 22 InvestigatorsImpact of triglyceride levels beyond low-density lipoprotein cholesterol after acute coronary syndrome in the PROVE IT-TIMI 22 trialJ Am Coll Cardiol200851772473018279736
   PubMed Web of Science ®Google Scholar
• SchwartzGGAbtMBaoWFasting triglycerides predict recurrent ischemic events in patients with acute coronary syndrome treated with statinsJ Am Coll Cardiol201565212267227526022813
   PubMed Web of Science ®Google Scholar
• RosensonRSDavidsonMHHirshBJKathiresanSGaudetDGenetics and causality of triglyceride-rich lipoproteins in atherosclerotic cardiovascular diseaseJ Am Coll Cardiol201464232525254025500239
   PubMed Web of Science ®Google Scholar
• KotwalSJunMSullivanDPerkovicVNealBOmega 3 fatty acids and cardiovascular outcomes: systematic review and meta-analysisCirc Cardiovasc Qual Outcomes20125680881823110790
   PubMed Web of Science ®Google Scholar
• JunMFooteCLvJEffects of fibrates on cardiovascular outcomes: a systematic review and meta-analysisLancet201037597291875188420462635
   PubMed Web of Science ®Google Scholar
• NordestgaardBGVarboATriglycerides and cardiovascular diseaseLancet2014384994362663525131982
   PubMed Web of Science ®Google Scholar
• DoRWillerCJSchmidtEMCommon variants associated with plasma triglycerides and risk for coronary artery diseaseNat Genet201345111345135224097064
   PubMed Web of Science ®Google Scholar
• ZhengCUpdates on apolipoprotein CIII: fulfilling promise as a therapeutic target for hypertriglyceridemia and cardiovascular diseaseCurr Opin Lipidol2014251353924345989
   PubMed Web of Science ®Google Scholar
• FazekasFEnzingerCRopeleSSchmidtHSchmidtRStrasser-FuchsSThe impact of our genes: consequences of the apolipoprotein E polymorphism in Alzheimer disease and multiple sclerosisJ Neurol Sci20062451–2353916631796
   PubMed Web of Science ®Google Scholar
• MahleyRWHuangYWeisgraberKHDetrimental effects of apolipoprotein E4: potential therapeutic targets in Alzheimer’s diseaseCurr Alzheimer Res20074553754018220516
   PubMed Web of Science ®Google Scholar
• DoRStitzielNOWonHHExome sequencing identifies rare LDLR and APOA5 alleles conferring risk for myocardial infarctionNature2015518753710210625487149
   PubMed Web of Science ®Google Scholar
• GinsbergHNNew perspectives on atherogenesis: role of abnormal triglyceride-rich lipoprotein metabolismCirculation2002106162137214212379586
   PubMed Web of Science ®Google Scholar
• XiaoCHsiehJAdeliKLewisGFGut-liver interaction in triglyceride-rich lipoprotein metabolismAm J Physiol Endocrinol Metab20113013E429E44621693689
   PubMed Web of Science ®Google Scholar
• GinsbergHNLipoprotein physiologyEndocrinol Metab Clin North Am19982735035199785050
   PubMed Web of Science ®Google Scholar
• BeigneuxAPDaviesBSBensadounAFongLGYoungSGGPIHBP1, a GPI-anchored protein required for the lipolytic processing of triglyceride-rich lipoproteinsJ Lipid Res200950supplS57S6218854402
   PubMedGoogle Scholar
• DaviesBSBeigneuxAPBarnesRH2ndGPIHBP1 is responsible for the entry of lipoprotein lipase into capillariesCell Metab2010121425220620994
   PubMed Web of Science ®Google Scholar
• GoldbergIJScheraldiCAYacoubLKSaxenaUBisgaierCLLipoprotein ApoC-II activation of lipoprotein lipase. Modulation by apolipoprotein A-IVJ Biol Chem19902658426642722307668
   PubMed Web of Science ®Google Scholar
• JohansenCTKathiresanSHegeleRAGenetic determinants of plasma triglyceridesJ Lipid Res201152218920621041806
   PubMed Web of Science ®Google Scholar
• MillerMStoneNJBallantyneCTriglycerides and cardiovascular disease: a scientific statement from the American Heart AssociationCirculation2011123202292233321502576
   PubMed Web of Science ®Google Scholar
• BrahmAHegeleRAHypertriglyceridemiaNutrients201353981100123525082
   PubMed Web of Science ®Google Scholar
• VarboABennMTybjaerg-HansenAJorgensenABFrikke- SchmidtRNordestgaardBGRemnant cholesterol as a causal risk factor for ischemic heart diseaseJ Am Coll Cardiol201361442743623265341
   PubMed Web of Science ®Google Scholar
• ThomsenMVarboATybjaerg-HansenANordestgaardBGLow nonfasting triglycerides and reduced all-cause mortality: a mendelian randomization studyClin Chem201460573774624436475
   PubMed Web of Science ®Google Scholar
• HodisHNTriglyceride-rich lipoprotein remnant particles and risk of atherosclerosisCirculation199999222852285410359725
   PubMed Web of Science ®Google Scholar
• NordestgaardBGStenderSKjeldsenKReduced atherogenesis in cholesterol-fed diabetic rabbits. Giant lipoproteins do not enter the arterial wallArteriosclerosis1988844214283395278
   PubMedGoogle Scholar
• RappJHLespineAHamiltonRLTriglyceride-rich lipoproteins isolated by selected-affinity anti-apolipoprotein B immunosorption from human atherosclerotic plaqueArterioscler Thromb19941411176717747947602
   PubMedGoogle Scholar
• NordestgaardBGWoottonRLewisBSelective retention of VLDL, IDL, and LDL in the arterial intima of genetically hyperlipidemic rabbits in vivo. Molecular size as a determinant of fractional loss from the intima-inner mediaArterioscler Thromb Vasc Biol19951545345427749867
   PubMed Web of Science ®Google Scholar
• Yla-HerttualaSJaakkolaOEhnholmCCharacterization of two lipoproteins containing apolipoproteins B and E from lesion-free human aortic intimaJ Lipid Res19882955635723137302
   PubMed Web of Science ®Google Scholar
• GoldsteinJLHoYKBrownMSInnerarityTLMahleyRWCholesteryl ester accumulation in macrophages resulting from receptor-mediated uptake and degradation of hypercholesterolemic canine beta-very low density lipoproteinsJ Biol Chem19802555183918487354064
   PubMed Web of Science ®Google Scholar
• PitasREInnerarityTLMahleyRWFoam cells in explants of atherosclerotic rabbit aortas have receptors for beta-very low density lipoproteins and modified low density lipoproteinsArteriosclerosis1983312126297442
   PubMedGoogle Scholar
• BattKVPatelLBothamKMSucklingKEChylomicron remnants and oxidised low density lipoprotein have differential effects on the expression of mRNA for genes involved in human macrophage foam cell formationJ Mol Med (Berl)200482744945815156288
   PubMed Web of Science ®Google Scholar
• AungHHLameMWGohilKAnCIWilsonDWRutledgeJCInduction of ATF3 gene network by triglyceride-rich lipoprotein lipolysis products increases vascular apoptosis and inflammationArterioscler Thromb Vasc Biol20133392088209623868936
   PubMed Web of Science ®Google Scholar
• SunCAlkhouryKWangYIIRF-1 and miRNA126 modulate VCAM-1 expression in response to a high-fat mealCirc Res201211181054106422874466
   PubMed Web of Science ®Google Scholar
• GowerRMWuHFosterGACD11c/CD18 expression is upregulated on blood monocytes during hypertriglyceridemia and enhances adhesion to vascular cell adhesion molecule-1Arterioscler Thromb Vasc Biol201131116016621030716
   PubMed Web of Science ®Google Scholar
• WangLGillRPedersenTLHigginsLJNewmanJWRutledgeJCTriglyceride-rich lipoprotein lipolysis releases neutral and oxidized FFAs that induce endothelial cell inflammationJ Lipid Res200950220421318812596
   PubMed Web of Science ®Google Scholar
• DoiHKugiyamaKOkaHRemnant lipoproteins induce proatherothrombogenic molecules in endothelial cells through a redox-sensitive mechanismCirculation2000102667067610931808
   PubMed Web of Science ®Google Scholar
• WangYIBettaiebASunCTriglyceride-rich lipoprotein modulates endothelial vascular cell adhesion molecule (VCAM)-1 expression via differential regulation of endoplasmic reticulum stressPLoS One2013810e7832224205197
   PubMed Web of Science ®Google Scholar
• HuaSTargeting sites of inflammation: intercellular adhesion molecule-1 as a target for novel inflammatory therapiesFront Pharmacol2013412724109453
   PubMed Web of Science ®Google Scholar
• AlipourAvan OostromAJIzraeljanALeukocyte activation by triglyceride-rich lipoproteinsArterioscler Thromb Vasc Biol200828479279718218988
   PubMed Web of Science ®Google Scholar
• HadiHACarrCSAl SuwaidiJEndothelial dysfunction: cardiovascular risk factors, therapy, and outcomeVasc Health Risk Manag20051318319817319104
   PubMedGoogle Scholar
• ShinHKKimYKKimKYLeeJHHongKWRemnant lipoprotein particles induce apoptosis in endothelial cells by NAD(P)H oxidase-mediated production of superoxide and cytokines via lectin-like oxidized low-density lipoprotein receptor-1 activation: prevention by cilostazolCirculation200410981022102814967724
   PubMed Web of Science ®Google Scholar
• OlufadiRByrneCDEffects of VLDL and remnant particles on plateletsPathophysiol Haemost Thromb2006353–428129116877877
   PubMedGoogle Scholar
• SteffelJLuscherTFTannerFCTissue factor in cardiovascular diseases: molecular mechanisms and clinical implicationsCirculation2006113572273116461845
   PubMed Web of Science ®Google Scholar
• PatelSPuranikRNakhlaSAcute hypertriglyceridaemia in humans increases the triglyceride content and decreases the anti-inflammatory capacity of high density lipoproteinsAtherosclerosis2009204242442819111829
   PubMed Web of Science ®Google Scholar
• ZhengXYLiuLRemnant-like lipoprotein particles impair endothelial function: direct and indirect effects on nitric oxide synthaseJ Lipid Res20074881673168017496332
   PubMed Web of Science ®Google Scholar
• Wyler von BallmoosMCHaringBSacksFMThe risk of cardiovascular events with increased apoplipoprotein CIII: a systematic review and meta-analysisJ Clin Lipidol2015949851026228667
   PubMed Web of Science ®Google Scholar
• KawakamiAAikawaMAlcaidePLuscinskasFWLibbyPSacksFMApolipoprotein CIII induces expression of vascular cell adhesion molecule-1 in vascular endothelial cells and increases adhesion of monocytic cellsCirculation2006114768168716894036
   PubMed Web of Science ®Google Scholar
• Juntti-BerggrenLRefaiEAppelskogIApolipoprotein CIII promotes Ca2+-dependent beta cell death in type 1 diabetesProc Natl Acad Sci U S A200410127100901009415210953
   PubMed Web of Science ®Google Scholar
• SolEMSundstenTBergstenPRole of MAPK in apolipoprotein CIII-induced apoptosis in INS-1E cellsLipids Health Dis20098319196457
   PubMed Web of Science ®Google Scholar
• KonesRMolecular sources of residual cardiovascular risk, clinical signals, and innovative solutions: relationship with subclinical disease, undertreatment, and poor adherence: implications of new evidence upon optimizing cardiovascular patient outcomesVasc Health Risk Manag2013961767024174878
   PubMedGoogle Scholar
• CrosbyJPelosoGMAuerPLLoss-of-function mutations in APOC3, triglycerides, and coronary diseaseN Engl J Med20143711223124941081
   PubMed Web of Science ®Google Scholar
• JorgensenABFrikke-SchmidtRNordestgaardBGTybjaerg-HansenALoss-of-function mutations in APOC3 and risk of ischemic vascular diseaseN Engl J Med20143711324124941082
   PubMed Web of Science ®Google Scholar
• Triglyceride Coronary Disease Genestics Consortium and Emerging Risk Factors CollaborationSarwarNSandhuMSTriglyceride-mediated pathways and coronary disease: collaborative analysis of 101 studiesLancet201037597261634163920452521
   PubMed Web of Science ®Google Scholar
• FolsomARPeacockJMDemerathEBoerwinkleEVariation in ANGPTL4 and risk of coronary heart disease: the Atherosclerosis Risk in Communities StudyMetabolism200857111591159618940399
   PubMed Web of Science ®Google Scholar
• VarboABennMTybjaerg-HansenANordestgaardBGElevated remnant cholesterol causes both low-grade inflammation and ischemic heart disease, whereas elevated low-density lipoprotein cholesterol causes ischemic heart disease without inflammationCirculation2013128121298130923926208
   PubMed Web of Science ®Google Scholar
• Di AngelantonioESarwarNPerryPMajor lipids, apolipoproteins, and risk of vascular diseaseJAMA2009302181993200019903920
   PubMed Web of Science ®Google Scholar
• FaergemanOHolmeIFayyadRPlasma triglycerides and cardiovascular events in the treating to new targets and incremental decrease in end-points through aggressive lipid lowering trials of statins in patients with coronary artery diseaseAm J Cardiol2009104445946319660594
   PubMed Web of Science ®Google Scholar
• FreibergJJTybjaerg-HansenAJensenJSNordestgaardBGNon fasting triglycerides and risk of ischemic stroke in the general populationJAMA2008300182142215219001625
   PubMed Web of Science ®Google Scholar
• BansalSBuringJERifaiNMoraSSacksFMRidkerPMFasting compared with nonfasting triglycerides and risk of cardiovascular events in womenJAMA2007298330931617635891
   PubMed Web of Science ®Google Scholar
• NordestgaardBGBennMSchnohrPTybjaerg-HansenANonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and womenJAMA2007298329930817635890
   PubMed Web of Science ®Google Scholar
• BerglundLBrunzellJDGoldbergACEvaluation and treatment of hypertriglyceridemia: an Endocrine Society clinical practice guidelineJ Clin Endocrinol Metab20129792969298922962670
   PubMed Web of Science ®Google Scholar
• JacobsonTAItoMKMakiKCNational Lipid Association recommendations for patient-centered management of dyslipidemia: part 1 – executive summaryJ Clin Lipidol20148547348825234560
   PubMed Web of Science ®Google Scholar
• StoneNJRobinsonJGLichtensteinAH2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice GuidelinesJ Am Coll Cardiol20146325 pt B2889293424239923
   PubMed Web of Science ®Google Scholar
• BirjmohunRSHuttenBAKasteleinJJStroesESEfficacy and safety of high-density lipoprotein cholesterol-increasing compounds: a meta-analysis of randomized controlled trialsJ Am Coll Cardiol200545218519715653014
   PubMed Web of Science ®Google Scholar
• RobinsonJGWangSSmithBJJacobsonTAMeta-analysis of the relationship between non-high-density lipoprotein cholesterol reduction and coronary heart disease riskJ Am Coll Cardiol200953431632219161879
   PubMed Web of Science ®Google Scholar
• DavidsonMHBaysHESteinETRIMS InvestigatorsEffects of fenofibrate on atherogenic dyslipidemia in hypertriglyceridemic subjectsClin Cardiol200629626827316796078
   PubMed Web of Science ®Google Scholar
• FarnierMUpdate on the clinical utility of fenofibrate in mixed dys-lipidemias: mechanisms of action and rational prescribingVasc Health Risk Manag200845991100019183747
   PubMedGoogle Scholar
• FrickMHEloOHaapaKHelsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart diseaseN Engl J Med198731720123712453313041
   PubMed Web of Science ®Google Scholar
• RubinsHBRobinsSJCollinsDGemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study GroupN Engl J Med1999341641041810438259
   PubMed Web of Science ®Google Scholar
• The BIP Study GroupSecondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease. The Bezafibrate Infarction Prevention (BIP) studyCirculation20001021212710880410
   PubMed Web of Science ®Google Scholar
• KeechASimesRJBarterPEffects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trialLancet200536695001849186116310551
   PubMed Web of Science ®Google Scholar
• LeeMSaverJLTowfighiAChowJOvbiageleBEfficacy of fibrates for cardiovascular risk reduction in persons with atherogenic dyslipidemia: a meta-analysisAtherosclerosis2011217249249821592479
   PubMed Web of Science ®Google Scholar
• DavidsonMHArmaniAMcKenneyJMJacobsonTASafety considerations with fibrate therapyAm J Cardiol2007993C18C
   PubMed Web of Science ®Google Scholar
• ChangJTStaffaJAParksMGreenLRhabdomyolysis with HMG-CoA reductase inhibitors and gemfibrozil combination therapyPharmacoepidemiol Drug Saf200413741742615269925
   PubMed Web of Science ®Google Scholar
• KyrklundCBackmanJTNeuvonenMNeuvonenPJGemfibrozil increases plasma pravastatin concentrations and reduces pravastatin renal clearanceClin Pharmacol Ther200373653854412811363
   PubMed Web of Science ®Google Scholar
• GinsbergHNElamMBLovatoLCEffects of combination lipid therapy in type 2 diabetes mellitusN Engl J Med2010362171563157420228404
   PubMed Web of Science ®Google Scholar
• BruckertELabreucheJAmarencoPMeta-analysis of the effect of nicotinic acid alone or in combination on cardiovascular events and atherosclerosisAtherosclerosis2010210235336120079494
   PubMed Web of Science ®Google Scholar
• LavignePMKarasRHThe current state of niacin in cardiovascular disease prevention: a systematic review and meta-regressionJ Am Coll Cardiol201361444044623265337
   PubMed Web of Science ®Google Scholar
• CannerPLBergeKGWengerNKFifteen year mortality in coronary drug project patients: long-term benefit with niacinJ Am Coll Cardiol198686124512553782631
   PubMed Web of Science ®Google Scholar
• HPS2-THRIVE Collaborative GroupHPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatmentEur Heart J201334171279129123444397
   PubMed Web of Science ®Google Scholar
• BodenWEProbstfieldJLAndersonTNiacin in patients with low HDL cholesterol levels receiving intensive statin therapyN Engl J Med2011365242255226722085343
   PubMed Web of Science ®Google Scholar
• GuytonJRSleeAEAndersonTRelationship of lipoproteins to cardiovascular events: the AIM-HIGH Trial (atherothrombosis intervention in metabolic syndrome with low HDL/high triglycerides and impact on global health outcomes)J Am Coll Cardiol201362171580158423916935
   PubMed Web of Science ®Google Scholar
• GuytonJRBaysHESafety considerations with niacin therapyAm J Cardiol2007996A22C31C
   PubMed Web of Science ®Google Scholar
• AstraZenecaEpanova Prescribing Information 2014 Available from: http://www.astrazeneca-us.com/pi/epanova.pdfAccessed August 26, 2015
   Google Scholar
• GlaxoSmithKline [webpage on the Internet]Lovaza Prescribing Information 2014 Available from: https://www.gsksource.com/gskprm/htdocs/documents/LOVAZA-PI-PIL.PDFAccessed August 26, 2015
   Google Scholar
• Trygg Pharma [webpage on the Internet]Omtryg Prescribing Information 2014 Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/204977s000lbl.pdfAccessed August 26, 2015
   Google Scholar
• Amarin Corporation [webpage on the Internet]Vascepa Prescibing Information 2014 Available from: www.vascepa.com/full-prescribing-information.pdfAccessed August 26, 2015
   Google Scholar
• HarrisWSn-3 fatty acids and serum lipoproteins: human studiesAm J Clin Nutr1997655 suppl1645S1654S9129504
   PubMed Web of Science ®Google Scholar
• GISSI-Prevenzione InvestigatorsDietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto miocardicoLancet1999354917744745510465168
   PubMed Web of Science ®Google Scholar
• YokoyamaMOrigasaHMatsuzakiMEffects of eicosap-entaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysisLancet200736995671090109817398308
   PubMed Web of Science ®Google Scholar
• KromhoutDGiltayEJGeleijnseJMAlpha Omega Trial Groupn-3 fatty acids and cardiovascular events after myocardial infarctionN Engl J Med2010363212015202620929341
   PubMed Web of Science ®Google Scholar
• RauchBSchieleRSchneiderSOMEGA, a randomized, placebo-controlled trial to test the effect of highly purified omega-3 fatty acids on top of modern guideline-adjusted therapy after myocardial infarctionCirculation2010122212152215921060071
   PubMed Web of Science ®Google Scholar
• Clinicaltrials.gov. [webpage on the Internet]A Study of AMR101 to Evaluate Its Ability to Reduce Cardiovascular Events in High Risk Patients with Hypertriglyceridemia and on Statin. The Primary Objective is to Evaluate the Effect of 4 g/Day AMR101 for Preventing the Occurrence of a First Major Cardiovascular Event. (REDUCE-IT)Clinicaltrials.gov2014 Available from: https://clinicaltrials.gov/ct2/show/NCT01492361Accessed August 20, 2015
   Google Scholar
• Clinicaltrials.gov. [webpage on the Internet]Outcomes Study to Assess Statin Residual Risk Reduction with Epanova in High CV Risk Patients with Hypertriglyceridemia (STRENGTH)2015 Available from: https://clinicaltrials.gov/ct2/show/NCT02104817Accessed August 20, 2015
   Google Scholar
• KasteleinJJMakiKCSusekovAOmega-3 free fatty acids for the treatment of severe hypertriglyceridemia: the Epanova for lowering very high triglycerides (EVOLVE) trialJ Clin Lipidol2014819410624528690
   PubMed Web of Science ®Google Scholar
• WangCHarrisWSChungMn-3 Fatty acids from fish or fish-oil supplements, but not alpha-linolenic acid, benefit cardiovascular disease outcomes in primary- and secondary-prevention studies: a systematic reviewAm J Clin Nutr200684151716825676
   PubMed Web of Science ®Google Scholar
• BaysHEBallantyneCMKasteleinJJIsaacsohnJLBraeckmanRASoniPNEicosapentaenoic acid ethyl ester (AMR101) therapy in patients with very high triglyceride levels (from the multi-center, placebo-controlled, randomized, double-blind, 12-week study with an open-label extension [MARINE] trial)Am J Cardiol2011108568269021683321
   PubMed Web of Science ®Google Scholar
• BallantyneCMBaysHEKasteleinJJEfficacy and safety of eicosapentaenoic acid ethyl ester (AMR101) therapy in statin-treated patients with persistent high triglycerides (from the ANCHOR study)Am J Cardiol2012110798499222819432
   PubMed Web of Science ®Google Scholar
• FilionKBEl KhouryFBielinskiMSchillerIDendukuriNBrophyJMOmega-3 fatty acids in high-risk cardiovascular patients: a meta-analysis of randomized controlled trialsBMC Cardiovasc Disord2010102420525225
   PubMed Web of Science ®Google Scholar
• HarrisWSGinsbergHNArunakulNSafety and efficacy of Omacor in severe hypertriglyceridemiaJ Cardiovasc Risk199745–63853919865671
   PubMedGoogle Scholar
• KostapanosMSMilionisHJElisafMSRosuvastatin-associated adverse effects and drug-drug interactions in the clinical setting of dyslipidemiaAm J Cardiovasc Drugs2010101112820104931
   PubMed Web of Science ®Google Scholar
• GaudetDAlexanderVJDianeBAn antisense inhibitor of apolipoprotein C-III substantially decreases fasting apolipoprotein C-III and triglyceride levels in LPL deficiencyJ Clin Lipidol201483353354
   Google Scholar
• HuffMWHegeleRAApolipoprotein C-III: going back to the future for a lipid drug targetCirc Res2013112111405140823704213
   PubMed Web of Science ®Google Scholar
• GaudetDMethotJKasteleinJGene therapy for lipoprotein lipase deficiencyCurr Opin Lipidol201223431032022691709
   PubMed Web of Science ®Google Scholar
• TothPPEmerging LDL therapies: mipomersen-antisense oligonucleotide therapy in the management of hypercholesterolemiaJ Clin Lipidol201373 supplS6S1023642326
   PubMed Web of Science ®Google Scholar
• TothPPShahPKWilkinsonMJDavidsonMHMcCulloughPAUse of microsomal triglyceride transfer protein inhibitors in patients with homozygous familial hypercholesterolemia: translating clinical trial experience into clinical practiceRev Cardiovasc Med201415111024762461
   PubMed Web of Science ®Google Scholar
• National Cholesterol Education Program (NCEP) Expert Panel on Detection Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final reportCirculation2002106253143342112485966
   PubMed Web of Science ®Google Scholar
• FriedewaldWTLevyRIFredricksonDSEstimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifugeClin Chem19721864995024337382
   PubMed Web of Science ®Google Scholar
• HermansMPAhnSARousseauMFNovel unbiased equations to calculate triglyceride-rich lipoprotein cholesterol from routine non-fasting lipidsCardiovasc Diabetol2014135624612479
   PubMed Web of Science ®Google Scholar
• MartinSSBlahaMJElshazlyMBFriedewald-estimated versus directly measured low-density lipoprotein cholesterol and treatment implicationsJ Am Coll Cardiol201362873273923524048
   PubMed Web of Science ®Google Scholar
• AnderssonCLyassAVasanRSMassaroJMD’AgostinoRBSrRobinsSJLong-term risk of cardiovascular events across a spectrum of adverse major plasma lipid combinations in the Framingham Heart StudyAm Heart J2014168687888325458651
   PubMed Web of Science ®Google Scholar
• SharrettARBallantyneCMCoadySACoronary heart disease prediction from lipoprotein cholesterol levels, triglycerides, lipoprotein(a), apolipoproteins A-I and B, and HDL density sub-fractions: the Atherosclerosis Risk in Communities (ARIC) StudyCirculation2001104101108111311535564
   PubMed Web of Science ®Google Scholar
• AssmannGSchulteHThe importance of triglycerides: results from the Prospective Cardiovascular Munster (PROCAM) StudyEur J Epidemiol19928suppl 1991031505660
   PubMedGoogle Scholar
• KamannaVSKashyapMLMechanism of action of niacinAm J Cardiol20081018A20B26B18157959
   PubMed Web of Science ®Google Scholar
• BalkEMLichtensteinAHChungMKupelnickBChewPLauJEffects of omega-3 fatty acids on serum markers of cardiovascular disease risk: a systematic reviewAtherosclerosis20061891193016530201
   PubMed Web of Science ®Google Scholar
• MortonAFurtadoJAmerineWKlingDDavidsonMThe effect of omega-3 carboxylic acids on apolipoprotein CIII containing lipoproteins in moderate to severe hypertriglyceridemiaCirculation2014130suppl 1A16864
   Google Scholar
• WeintraubHSOverview of prescription omega-3 fatty acid products for hypertriglyceridemiaPostgrad Med2014126771825387209
   PubMed Web of Science ®Google Scholar
• WattsGFOoiEMChanDCDemystifying the management of hypertriglyceridaemiaNat Rev Cardiol2013101164866124060958
   PubMed Web of Science ®Google Scholar